Certara, Inc. (NASDAQ:CERT) Receives Consensus Rating of “Moderate Buy” from Analysts

Certara, Inc. (NASDAQ:CERT) has been given a consensus rating of “Moderate Buy” by the fifteen ratings firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation, seven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $12.9091.

Several equities analysts have commented on CERT shares. Weiss Ratings restated a “sell (d+)” rating on shares of Certara in a research note on Monday. Stephens lowered their target price on Certara from $15.00 to $12.00 and set an “overweight” rating for the company in a research note on Friday, December 12th. Rothschild & Co Redburn started coverage on Certara in a report on Friday, November 21st. They set a “buy” rating and a $10.00 price target on the stock. Zacks Research upgraded Certara from a “strong sell” rating to a “hold” rating in a research note on Friday, September 5th. Finally, KeyCorp boosted their price objective on Certara from $15.00 to $16.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 8th.

Certara Price Performance

CERT opened at $8.86 on Wednesday. The stock’s 50-day moving average price is $9.58 and its 200 day moving average price is $10.64. Certara has a 12-month low of $8.02 and a 12-month high of $15.69. The firm has a market cap of $1.41 billion, a price-to-earnings ratio of 126.57 and a beta of 1.46. The company has a current ratio of 2.09, a quick ratio of 2.09 and a debt-to-equity ratio of 0.27.

Certara (NASDAQ:CERT) last announced its earnings results on Thursday, November 6th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.03. The company had revenue of $104.62 million during the quarter, compared to analysts’ expectations of $104.53 million. Certara had a return on equity of 5.18% and a net margin of 2.62%.During the same period last year, the business posted $0.13 EPS. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. As a group, sell-side analysts expect that Certara will post 0.28 earnings per share for the current year.

Institutional Investors Weigh In On Certara

Several institutional investors have recently modified their holdings of CERT. Charles Schwab Investment Management Inc. increased its holdings in Certara by 5.3% in the first quarter. Charles Schwab Investment Management Inc. now owns 797,610 shares of the company’s stock valued at $7,896,000 after buying an additional 40,218 shares during the last quarter. Invesco Ltd. boosted its position in shares of Certara by 0.3% during the 1st quarter. Invesco Ltd. now owns 394,037 shares of the company’s stock worth $3,901,000 after acquiring an additional 1,285 shares in the last quarter. Nuveen LLC acquired a new position in shares of Certara during the 1st quarter worth about $2,676,000. Northern Trust Corp increased its holdings in shares of Certara by 4.5% in the 1st quarter. Northern Trust Corp now owns 916,299 shares of the company’s stock valued at $9,071,000 after acquiring an additional 39,289 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its position in shares of Certara by 13.6% during the 1st quarter. Ameriprise Financial Inc. now owns 4,295,566 shares of the company’s stock worth $42,526,000 after acquiring an additional 515,911 shares in the last quarter. 73.96% of the stock is owned by hedge funds and other institutional investors.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.